Combination Therapy with Neuraminidase and Polymerase Inhibitors in Nude Mice Infected with Influenza Virus

Journal of Infectious Diseases

Volumn 217, Issue 6, 2018, Pages 887-896

  Kiso, Maki ^a   Lopes, Tiago J S ^a,b   Yamayoshi, Seiya ^a   Ito, Mutsumi ^a   Yamashita, Makoto ^a   Nakajima, Noriko ^c   Hasegawa, Hideki ^c   Neumann, Gabriele ^b   Kawaoka, Yoshihiro ^a,b,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Combination therapy; Drug resistance; Influenza; Neuraminidase inhibitor; Polymerase inhibitor

Indexed keywords

FAVIPIRAVIR; LANINAMIVIR; OSELTAMIVIR; AMIDE; ANTIVIRUS AGENT; ENZYME INHIBITOR; NUCLEIC ACID SYNTHESIS INHIBITOR; PYRAZINE DERIVATIVE; SIALIDASE; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IMMUNOCOMPROMISED PATIENT; INFLUENZA A; INFLUENZA A VIRUS; LUNG PARENCHYMA; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECT; INFLUENZA A VIRUS (H1N1); LUNG; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; VIROLOGY;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MICE; MICE, INBRED BALB C; MICE, NUDE; NEURAMINIDASE; NUCLEIC ACID SYNTHESIS INHIBITORS; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PYRAZINES; ZANAMIVIR;

EID: 85042907711     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix606     Document Type: Article

References (50)

1. Li TC, Chan MC, Lee N. Clinical implications of antiviral resistance in influenza. Viruses 2015; 7:4929-44.
2. McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res 2016; 129:21-38.
3. Schirmer P, Holodniy M. Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin Drug Saf 2009; 8:357-71.
4. Alame MM, Massaad E, Zaraket H. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections. Front Microbiol 2016; 7:450.
5. Kiso M, Kubo S, Ozawa M, et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog 2010; 6:e1000786.
6. Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother 2010; 21:71-84.
7. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51:1167-75.
8. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013; 98:174-85.
9. Laborda P, Wang SY, Voglmeir J. Influenza neuraminidase inhibitors: synthetic approaches, derivatives and biological activity. Molecules 2016; 21. pii:E1513.
10. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729-37.
11. Muthuri SG, Venkatesan S, Myles PR, et al; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395-404.
12. Kumar D, Michaels MG, Morris MI, et al; American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521-6.
13. Oboho IK, Reed C, Gargiullo P, et al. Benefit of early initiation of influenza antiviral treatment to pregnant women hospitalized with laboratory-confirmed influenza. J Infect Dis 2016; 214:507-15.
14. Renaud C, Boudreault AA, Kuypers J, et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011; 17:653-60; quiz 765.
15. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009; 199:1435-41.
16. Hurt AC, Leang SK, Tiedemann K, et al. Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient. Influenza Other Respir Viruses 2013; 7:904-8.
17. Tamura D, DeBiasi RL, Okomo-Adhiambo M, et al. Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir. J Infect Dis 2015; 212:1209-13.
18. Rogers MB, Song T, Sebra R, et al. Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection. MBio 2015; 6. doi:10.1128/mBio.02464-14.
19. Moore C, Galiano M, Lackenby A, et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis 2011; 203:18-24.
20. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363:1381-2.
21. L'Huillier AG, Abed Y, Petty TJ, et al. E119D neuraminidase mutation conferring pan-resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient. J Infect Dis 2015; 212:1726-34.
22. Tamura D, DeBiasi RL, Okomo-Adhiambo M, et al. Emergence of multidrug-resistant influenza A(H1N1) pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir. J Infect Dis 2015; 212:1209-13.
23. Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16:1068-75.
24. Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Knipe DM, Howley PM, Cohen JI, et al, eds. Fields Virology. 6th ed. Vol 1. Philadelphia, PA: Lippincott Williams & Wilkins, 2013:1186-243.
25. Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol 2014; 8:22-9.
26. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46:977-81.
27. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49:981-6.
28. Toyama Chemical Co. Ltd. The new drug application approval of Avigan tablet 200 mg in Japan for the anti-influenza virus drug. https://www.toyama-chemical.co.jp/eng/news/news140324e.html. Accessed 24 March 2014.
29. Dunning J, Baillie JK, Cao B, Hayden FG; International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis 2014; 14:1259-70.
30. Kim WY, Young Suh G, Huh JW, et al; Korean Society of Critical Care Medicine H1N1 Collaborative. Triplecombination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 2011; 55:5703-9.
31. Zhou J, Yang XQ, Fu Z, et al. Increased pathogenesis and inflammation of airways from respiratory syncytial virus infection in T cell deficient nude mice. Med Microbiol Immunol 2008; 197:345-51.
32. Wells MA, Albrecht P, Ennis FA. Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. J Immunol 1981; 126:1036-41.
33. Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y. Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res 2011; 158:124-9.
34. Ruiz-Carrascoso G, Casas I, Pozo F, González-Vincent M, Pérez-Breña P. Prolonged shedding of amantadine-and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant. Antivir Ther 2010; 15:1059-63.
35. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178:1257-62.
36. Jackson D, Barclay W, Zürcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 2005; 55:162-9.
37. Samson M, Abed Y, Desrochers FM, et al. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir. Antimicrob Agents Chemother 2014; 58:5220-8.
38. Seo S, Englund JA, Nguyen JT, et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther 2013; 18:377-86.
39. Marathe BM, Wong SS, Vogel P, et al. Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice. Sci Rep 2016; 6:26742.
40. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 2001; 45:3403-8.
41. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41:742-50.
42. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47:2264-72.
43. Kubo S, Tokumitsu A, Tomozawa T, Kakuta M, Yamashita M. High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals. J Infect Chemother 2012; 18:69-74.
44. Baek YH, Song MS, Lee EY, et al. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors. J Virol 2015; 89:287-99.
45. Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011; 203:25-31.
46. Pizzorno A, Abed Y, Rheaume C, Bouhy X, Boivin G. Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets. Antimicrob Agents Chemother 2013; 57:1784-9.
47. Baranovich T, Wong SS, Armstrong J, et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013; 87:3741-51.
48. Sangawa H, Komeno T, Nishikawa H, et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 2013; 57:5202-8.
49. Jin Z, Tucker K, Lin X, et al. Biochemical evaluation of the inhibition properties of favipiravir and 2'-C-methyl-cytidine triphosphates against human and mouse norovirus RNA polymerases. Antimicrob Agents Chemother 2015; 59:7504-16.
50. Delang L, Segura Guerrero N, Tas A, et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 2014; 69:2770-84.